Showing 1 - 20 results of 330 for search '"Melanoma pathology"', query time: 1.47s Refine Results
1
Academic Journal
Clinicopathological analysis of acral melanoma in a single center: a study of 45 cases

Authors: Souza, Bruno de Castro e, Silva, Diego Henrique Morais, Miyashiro, Denis, Kakizaki, Priscila, Valente, Neusa Yuriko Sakai

Source: Revista da Associação Médica Brasileira. October 2020 66(10)

Subject Terms: Melanoma/epidemiology, Melanoma/pathology, Skin neoplasms

File Description: text/html

Access URL: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302020001001391

2
Experiences of resuming life after immunotherapy and associated survivorship care needs

Authors: Nadia C.W. Kamminga, Astrid A.M. van der Veldt, Margot C.W. Joosen, Karlijn de Joode, Arjen Joosse, Dirk J. Grünhagen, Tamar E.C. Nijsten, Marlies Wakkee, Marjolein Lugtenberg

Contributors: Dermatology, Medical Oncology, Radiology & Nuclear Medicine, Surgery, Tranzo, Scientific center for care and wellbeing, Arbeid & Gezondheid

Source: British Journal of Dermatology, 187(3), 381-391. Wiley-Blackwell Publishing Ltd
The British Journal of Dermatology, 187(3), 381-391. Wiley-Blackwell

Subject Terms: Humans, Immune Checkpoint Inhibitors, Immunologic Factors/therapeutic use, Immunotherapy, Melanoma/pathology, Neoplasms, Second Primary, Quality of Life/psychology, Survivors/psychology, Survivorship, SDG 3 - Good Health and Well-being, Neoplasms, Second Primary, Dermatology

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adf72e770b0493dd87aa020b2eee1cb8
http://www.scopus.com/inward/record.url?scp=85131946653&partnerID=8YFLogxK

3
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

Authors: Lars Bastholt, Marta Nyakas, Sandrine Marreaud, Ernest Marshall, Justyna Mierzynska, Gerard Groenewegen, Lutz Kretschmer, Leonel Hernandez-Aya, Mohammed M. Milhem, Michele Maio, Corneel Coens, Alain Algazi, Helena Kapiteijn, Paola Queirolo, Felix Kiecker, Pablo Luis Ortiz Romero, Friedegund Meier, Paul C. Nathan, Michal Lotem, Elaine Dunwoodie, Anna Maria Di Giacomo, Marcin Dzienis, Reinhard Dummer, Carmen Loquai, Alexander C.J. van Akkooi, Susana Puig, Marie-Thérèse Leccia, Frank Meiss, Florent Grange, Jean-Francois Baurain, Sigrun Hallmeyer, Daniil Stroyakovskiy, Axel Hauschild, Victoria Atkinson, Yoshio Kiyohara, Naoya Yamazaki, Andrew Haydon, Peter Mohr, Gil Bar-Sela, Michal Kicinski, Laurent Mortier, Andrzej Mackiewicz, Caroline Robert, Vincent Descamps, Virginia Ferraresi, John Walker, Céleste Lebbé, Erika Richtig, Rüdiger Hein, Jochen Utikal, Christian U. Blank, Tatsuya Takenouchi, Marie-Francoise Avril, Piotr Rutkowski, Ralf Gutzmer, Ashita Waterston, Clemens Krepler, Timothy Crook, Oliver Bechter, Kenji Yokota, Jean-Jacques Grob, Paolo A. Ascierto, Jun Aoi, Stéphane Dalle, Jean-Philippe Lacour, Ana Raimundo, Gerald P. Linette, Bernard Guillot, Michael C. Brown, Ragini R. Kudchadkar, Catriona M. McNeil, Philippe Saiag, Henrik Schmidt, Thomas Jouary, Rosalie Stephens, Xinni Song, Philippa Corrie, Richard Casasola, Patrick Terheyden, James Larkin, Catherine Barrow, Jessica C. Hassel, Dirk Schadendorf, Nageatte Ibrahim, Caroline Dutriaux, François Aubin, Jan-Christoph Simon, Bernard Fitzharris, Mario Mandalà, Carola Berking, Inge Marie Svane, Patrick Combemale, Jean-Philippe Arnault, Vanna Chiarion Sileni, Geke A. P. Hospers, Georgina V. Long, Marco Siano, Rahima Jamal, Claus Garbe, Christoph Hoeller, Stefan Suciu, Andrey Meshcheryakov, Andrew Bottomley, Matteo S. Carlino, Maria-Jose Passos, Maureen J.B. Aarts, Oddbjorn Straume, Wolf-Henning Boehncke, César Martins, Phillip Parente, Pietro Quaglino, Rutger H. T. Koornstra, Joseph Kerger, Lionel Geoffrois, Tanja Skytta, Max Levin, Alexander M.M. Eggermont, Suzana Matkovic, Kevin B. Kim, Peter Hersey, Takashi Inozume, Guzel Mukhametshina, Daniel Hendler, Laurent Machet, Alfonsus J M van den Eertwegh, Shahneen Sandhu, Adnan Khattak, Paul Lorigan, Lidija Sekulovic, Thierry Lesimple, Michael B. Jameson, Pier Francesco Ferrucci, Micaela Hernberg, Jacob Schachter

Contributors: Internal medicine, CCA - Cancer Treatment and quality of life, European Organisation for Research and Treatment of Cancer [Bruxelles] (EORTC), European Cancer Organisation [Bruxelles] (ECCO), Ospedale 'Santa Maria della Misericordia' = University Hospital 'Santa Maria della Misericordia', The University of Sydney, Princess Alexandra Hospital, Brisbane, University of Queensland [Brisbane], Centre Léon Bérard [Lyon], Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Edith Cowan University (ECU), Universitat de Barcelona (UB), The Christie NHS Foundation Trust [Manchester, Royaume-Uni], Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology (MCMCC), Radboud University Medical Center [Nijmegen], Washington University School of Medicine in St. Louis, Washington University in Saint Louis (WUSTL), University Hospital of Siena, Amsterdam UMC - Amsterdam University Medical Center, Hôpital de la Timone [CHU - APHM] (TIMONE), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hannover Medical School [Hannover] (MHH), Centre Hospitalier de l'Université de Montréal (CHUM), Université de Montréal (UdeM), Merck & Co. Inc, AP-HP. Université Paris Saclay, Institut Gustave Roussy (IGR), University Medical Center [Utrecht], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université de Montpellier (UM), Merck Sharp & Dohme., Boehncke, Wolf-Henning

Source: The Lancet Oncology, 22(5), 655-664. Lancet Publishing Group
EORTC Melanoma Group 2021, ' Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial ', The Lancet Oncology, vol. 22, no. 5, pp. 655-664 . https://doi.org/10.1016/S1470-2045(21)00081-4
Lancet Oncology, 22, 655-664
Lancet Oncology
Lancet Oncology, 2021, 22 (5), pp.655-664. ⟨10.1016/S1470-2045(21)00081-4⟩
Lancet. Oncology, Vol. 22, No 5 (2021) pp. 655-664

Subject Terms: Medizin, Oncology, Hazard ratio, Clinical endpoint, Adjuvant therapy, Population, education.field_of_study, education, Medicine, business.industry, business, Pembrolizumab, Internal medicine, medicine.medical_specialty, Clinical trial, Randomized controlled trial, law.invention, law, Placebo, MESH: Adult, MESH: Aged, MESH: Double-Blind Method, MESH: Female, MESH: Humans, MESH: Male, MESH: Melanoma, MESH: Middle Aged, MESH: Neoplasm Staging, MESH: Quality of Life, MESH: Skin Neoplasms, MESH: Aged, 80 and over, MESH: Antibodies, Monoclonal, Humanized, [SDV.CAN]Life Sciences [q-bio]/Cancer, ddc:616, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized / therapeutic use, Double-Blind Method, Female, Humans, Male, Melanoma / drug therapy, Melanoma / mortality, Melanoma / pathology, Melanoma / psychology, Middle Aged, Neoplasm Staging, Quality of Life, Skin Neoplasms / drug therapy, Skin Neoplasms / mortality, Skin Neoplasms / pathology, Skin Neoplasms / psychology

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80dc0ff7069bff303dade337b8effb2d

4
Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany

Authors: Helmut Kehrer, Erika Richtig, Peter Koelblinger, Lukas Koch, Matthias Karasek, Christine Hafner, Julia Maria Ressler, Joanna Mangana, Christian Posch, Veronica Aedo-Lopez, Julian Kofler, Olivier Michielin, Christoph Hoeller, Felix Weihsengruber, Sofiya Latifyan, Rita Silmbrod

Contributors: University of Zurich, Ressler, Julia Maria

Source: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021)
Journal for Immunotherapy of Cancer
Journal for immunotherapy of cancer, vol. 9, no. 2, pp. e001701

Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282, Cancer Research, Pharmacology, Oncology, Molecular Medicine, Immunology, Immunology and Allergy, Internal medicine, medicine.medical_specialty, medicine, Treatment period, Melanoma, medicine.disease, Adverse effect, Talimogene laherparepvec, business.industry, business, Stage (cooking), Cohort, Progressive disease, Metastatic lesions, Oncolytic and Local Immunotherapy, oncolytic viruses, immunotherapy, melanoma, oncolytic virotherapy, Adult, Aged, Aged, 80 and over, Biological Products/adverse effects, Biological Products/therapeutic use, Disease Progression, Europe, Female, Herpesvirus 1, Human/immunology, Herpesvirus 1, Human/pathogenicity, Humans, Male, Melanoma/immunology, Melanoma/pathology, Melanoma/therapy, Middle Aged, Neoplasm Staging, Oncolytic Viruses/immunology, Oncolytic Viruses/pathogenicity, Retrospective Studies, Skin Neoplasms/immunology, Skin Neoplasms/pathology, Skin Neoplasms/therapy, Skin Neoplasms/virology, Time Factors, Treatment Outcome, 610 Medicine & health, 10177 Dermatology Clinic, 2723 Immunology and Allergy, 2403 Immunology, 1313 Molecular Medicine, 2730 Oncology, 3004 Pharmacology, 1306 Cancer Research

File Description: application/pdf; Nr._14_Real-life_ust_of_talimogene_laherparepvec.pdf - application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed27d867e0f6ae9e5fa254d7177dae2c
https://jitc.bmj.com/content/9/2/e001701.full

5
Skin melanoma deaths within 1 or 3 years from diagnosis in Europe

Authors: Paolo Broganelli, Lidia Sacchetto, Monika Hackl, Elizabeth Van Eycken, Rosario Tumino, Roberto Zanetti, Harry Comber, Jaume Galceran, Stefano Rosso, Christine Bouchardy, Laufey Tryggvadottir, Alexander Katalinic, Paul M. Walsh, Trude Eid Robsahm, Vesna Zadnik, Marieke W. J. Louwman

Source: International journal of cancer, Vol. 148, No 12 (2021) pp. 2898-2905

Subject Terms: ddc:613, Europe, Lethality, Melanoma, Prognostic factors, Trends, Adolescent, Adult, Age Factors, Aged, Child, Child, Preschool, Europe / epidemiology, Female, Humans, Incidence, Infant, Infant, Newborn, Male, Melanoma / diagnosis, Melanoma / mortality, Melanoma / pathology, Middle Aged, Mortality / trends, Multivariate Analysis, Registries, Sex Characteristics, Skin Neoplasms / diagnosis, Skin Neoplasms / mortality, Skin Neoplasms / pathology, Young Adult, Cancer Research, Oncology, Dermatology, medicine.medical_specialty, medicine, medicine.disease, Cancer, Lesion, medicine.symptom, business.industry, business, Skin melanoma, Incidence (epidemiology), Population, education.field_of_study, education, Overdiagnosis, Nodular melanoma

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fb0efc25461fe5469f1d676867abe44
https://archive-ouverte.unige.ch/unige:155405

6
An update on head and neck cancer: new entities and their histopathology, molecular background, treatment, and outcome

Authors: Simon Andreasen, Hani Ibrahim Channir, Christina Caroline Plaschke, Irene Wessel, Katalin Kiss, Linea Cecilie Melchior, Lauge Hjorth Mikkelsen, Jesper Grau Eriksen

Source: Andreasen, S, Kiss, K, Mikkelsen, L H, Channir, H I, Plaschke, C C, Melchior, L C, Eriksen, J G & Wessel, I 2019, ' An update on head and neck cancer: new entities and their histopathology, molecular background, treatment, and outcome ', APMIS Supplementum, vol. 127, no. 5, pp. 240-264 . https://doi.org/10.1111/apm.12901

Subject Terms: Microbiology (medical), General Medicine, Immunology and Allergy, Pathology and Forensic Medicine, Medicine, business.industry, business, Oncology, medicine.medical_specialty, Molecular pathology, Surgical pathology, Head and neck, Head and neck cancer, medicine.disease, Internal medicine, Histopathology, Sinonasal Tract, Cancer, World health, molecular pathology, pathology of tumors, prognostic markers, surgical pathology, Melanoma/pathology, Prognosis, Humans, Head and Neck Neoplasms/classification, Molecular Targeted Therapy, Oropharyngeal Neoplasms/pathology, Nose Neoplasms/pathology, Mouth Neoplasms/pathology, Electrochemotherapy, Salivary Gland Neoplasms/pathology

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2890004ec79e5128516ebaa0b72d698
https://doi.org/10.1111/apm.12901

HTML Full Text     PDF Full Text
7
Anatomic position determines oncogenic specificity in melanoma

Authors: Joshua M. Weiss, Miranda V. Hunter, Nelly M. Cruz, Arianna Baggiolini, Mohita Tagore, Yilun Ma, Sandra Misale, Michelangelo Marasco, Theresa Simon-Vermot, Nathaniel R. Campbell, Felicity Newell, James S. Wilmott, Peter A. Johansson, John F. Thompson, Georgina V. Long, John V. Pearson, Graham J. Mann, Richard A. Scolyer, Nicola Waddell, Emily D. Montal, Ting-Hsiang Huang, Philip Jonsson, Mark T.A. Donoghue, Christopher C. Harris, Barry S. Taylor, Tianhao Xu, Ronan Chaligné, Pavel V. Shliaha, Ronald Hendrickson, Achim A. Jungbluth, Cecilia Lezcano, Richard Koche, Lorenz Studer, Charlotte E. Ariyan, David B. Solit, Jedd D. Wolchok, Taha Merghoub, Neal Rosen, Nicholas K. Hayward, Richard M. White

Source: Weiss, J M, Hunter, M V, Cruz, N M, Baggiolini, A, Tagore, M, Ma, Y, Misale, S, Marasco, M, Simon-Vermot, T, Campbell, N R, Newell, F, Wilmott, J S, Johansson, P A, Thompson, J F, Long, G V, Pearson, J V, Mann, G J, Scolyer, R A, Waddell, N, Montal, E D, Huang, T H, Jonsson, P, Donoghue, M T A, Harris, C C, Taylor, B S, Xu, T, Chaligné, R, Shliaha, P V, Hendrickson, R, Jungbluth, A A, Lezcano, C, Koche, R, Studer, L, Ariyan, C E, Solit, D B, Wolchok, J D, Merghoub, T, Rosen, N, Hayward, N K & White, R M 2022, ' Anatomic position determines oncogenic specificity in melanoma ', Nature, vol. 604, pp. 354-361 . https://doi.org/10.1038/s41586-022-04584-6
Nature

Subject Terms: Gene, Rna profiling, Cancer research, Tropism, CRKL, Biology, DNA, chemistry.chemical_compound, chemistry, Cell of origin, Cutaneous melanoma, Melanoma, medicine.disease, medicine, skin and connective tissue diseases, Animals, Animals, Genetically Modified, Carcinogenesis/genetics, Foot, Hand, Humans, Melanoma/pathology, Nails, Oncogenes/genetics, Skin Neoplasms/genetics, Transcription, Genetic, Zebrafish/genetics, integumentary system, Multidisciplinary, Article

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b39395de5cccb872bc76acd0f99b36d
https://doi.org/10.1101/2020.11.14.383083

8
Clinicopathological analysis of acral melanoma in a single center: a study of 45 cases

Authors: Bruno de Castro e Souza, Diego Henrique Morais Silva, Denis Miyashiro, Priscila Kakizaki, Neusa Yuriko Sakai Valente

Source: Revista da Associação Médica Brasileira, Volume: 66, Issue: 10, Pages: 1391-1395, Published: 06 NOV 2020
Revista da Associação Médica Brasileira, Vol 66, Iss 10, Pp 1391-1395 (2020)
Revista da Associação Médica Brasileira v.66 n.10 2020
Revista da Associação Médica Brasileira
Associação Médica Brasileira (AMB)
instacron:AMB

Subject Terms: Melanoma/epidemiology, Melanoma/pathology, Skin neoplasms, Melanoma/epidemiologia, Melanoma/patologia, Neoplasias cutâneas, General Medicine, Evaluation period, Medicine, business.industry, business, Retrospective cohort study, Dermatology, medicine.medical_specialty, Advanced stage, Plantar region, Acral melanoma, Brazilian population, Single Center, Male patient, Medicine (General), R5-920, integumentary system

File Description: text/html

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fbe13bbd69a12dc301929d8291788900
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302020001001391&lng=en&tlng=en

9
Trametinib Induces the Stabilization of a Dual GNAQ p.Gly48Leu- and FGFR4 p.Cys172Gly-Mutated Uveal Melanoma. The Role of Molecular Modelling in Personalized Oncology

Authors: Mounir Trimech, Bettina Bisig, Alexandre Wicky, Krisztian Homicsko, Veronica Aedo-Lopez, Olivier Michielin, Fanny S Krebs, Vincent Zoete, Camille L. Gerard, Edoardo Missiaglia

Source: International Journal of Molecular Sciences
Volume 21
Issue 21
International Journal of Molecular Sciences, Vol 21, Iss 8021, p 8021 (2020)
International journal of molecular sciences, vol. 21, no. 21, pp. E8021

Subject Terms: precision oncology, molecular modelling, mutation, GNAQ, FGFR4, lcsh:Biology (General), lcsh:QH301-705.5, lcsh:Chemistry, lcsh:QD1-999, Amino Acid Sequence, Antineoplastic Agents/therapeutic use, Female, GTP-Binding Protein alpha Subunits, Gq-G11/chemistry, GTP-Binding Protein alpha Subunits, Gq-G11/genetics, GTP-Binding Protein alpha Subunits, Gq-G11/metabolism, Humans, Melanoma/drug therapy, Melanoma/genetics, Melanoma/metabolism, Melanoma/pathology, Middle Aged, Models, Molecular, Mutant Proteins/chemistry, Mutant Proteins/genetics, Mutant Proteins/metabolism, Mutation, Protein Conformation, Protein Stability, Pyridones/therapeutic use, Pyrimidinones/therapeutic use, Receptor, Fibroblast Growth Factor, Type 4/chemistry, Receptor, Fibroblast Growth Factor, Type 4/genetics, Receptor, Fibroblast Growth Factor, Type 4/metabolism, Sequence Homology, Signal Transduction, Uveal Neoplasms/drug therapy, Uveal Neoplasms/genetics, Uveal Neoplasms/metabolism, Uveal Neoplasms/pathology, Inorganic Chemistry, Organic Chemistry, Physical and Theoretical Chemistry, Computer Science Applications, Spectroscopy, Molecular Biology, General Medicine, Catalysis, Fibroblast growth factor receptor 4, Cancer research, Melanoma, medicine.disease, medicine, MEK inhibitor, Chemistry, Trametinib, Personalized oncology, Gq alpha subunit, biology.protein, biology, medicine.disease_cause, Article

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a720d088a79814508b85a7b35f96730d

HTML Full Text     PDF Full Text
10
Report
Amelanotic corneally displaced malignant conjunctival melanoma: a case report evaluated with impression cytology

Authors: Barros, Jeison de Nadai, Motono, Márcia, Costa, Felipe D'Almeida, Cunha, Marcelo Carvalho da, Chojniak, Martha Motono

Source: Arquivos Brasileiros de Oftalmologia. February 2014 77(1)

Subject Terms: Melanoma/pathology, Conjunctival neoplasms, Eye neoplasms, Cytological techniques, Diagnostic techniques, Ophthalmological, Humans, Female, Aged, Case report

File Description: text/html

Access URL: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492014000100057

Accede al texto completo
PDF Full Text
11
Quality-of-life assessment in French patients with metastatic melanoma in real life

Authors: Pierre-Emmanuel Stoebner, Thierry Lesimple, Philippe Saiag, Isabelle Borget, François Aubin, Stefan Michiels, Florence Granel-Brocard, A. Bardet, Florence Brunet-Possenti, Brigitte Dréno, Caroline Dutriaux, Eve Maubec, Céleste Lebbe, Henri Montaudié, Marie-Thérèse Leccia, Bernard Guillot, Laurent Mortier, Julie DeQuatrebarbes, Stéphane Dalle, Sophie Dalac, Jean-Jacques Grob, Clara Allayous, Jean-Philippe Arnault, Alain Dupuy, Marguerite Kandel, D. Legoupil, Marie Beylot-Barry

Contributors: Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Institut Gustave Roussy (IGR), Centre Léon Bérard [Lyon], Service de biostatistique et d'épidémiologie (SBE), Direction de la recherche clinique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Immunologie humaine, physiopathologie & immunothérapie (HIPI (UMR_S_976 / U976)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 (ONCO-THAI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Groupe hospitalier Saint-André, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Universitaire [Grenoble] (CHU), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Hôpital Ambroise Paré [AP-HP], Centre Hospitalier Universitaire de Nice (CHU Nice), Service de dermatologie [CHU d'Amiens-Picardie], CHU Amiens-Picardie, AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de dermatologie, vénéreologie et cancérologie cutanée [Hôpital de la Timone - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois], Service de dermatologie [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], CRLCC Eugène Marquis (CRLCC), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Avicennes University Hospital, Service de Dermatologie et Allergologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Service de Dermatologie [Rennes] = Dermatology [Rennes], CHU Pontchaillou [Rennes], Service de dermatologie [Nantes], Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes), AP-HP. Université Paris Saclay, Amgen Pfizer Merck Novartis Roche Janssen Biotech Meso Scale Diagnostics, MSD Array BioPharma Takeda Pharmaceutical Company Sanofi Pasteur British Microcirculation Society, BMS Institut National Du Cancer, INCa: DOC 16‐009, This work was supported by the French National Cancer Institute (DOC 16‐009)., Stéphane Dalle reports institutional research funding Roche, institutional research funding and nonfinancial support from Bristol‐Myers Squibb (BMS), and an immediate family member who is employed by Sanofi and owns stock or other ownership interest in the company. Aurélie Bardet was employed by Roche and held stock and other ownership interest in the company until March of 2018. Clara Allayous reports nonfinancial support from BMS, Amgen, and Roche outside the submitted work. Laurent Mortier reports personal fees and nonfinancial support from Roche, Novartis, BMS, and Merck Sharp & Dohme (MSD) outside the submitted work. Caroline Dutriaux reports personal fees from Roche, BMS, Novartis, MSD, and Pierre Fabre Laboratories outside the submitted work. Philippe Saiag reports research funding and personal fees from Roche, grants, personal fees, and nonfinancial support from BMS, MSD, Novartis, and Pierre Fabre Laboratories, and personal fees from Array, Sanofi, and Merck, all outside the submitted work. Henri Montaudié reports institutional research funding from LeoPharma, institutional research funding, personal fees, and nonfinancial support from BMS, personal fees from Pierre Fabre Laboratories and MSD, and nonfinancial support from Novartis, all outside the submitted work. Jean‐Phillipe Arnault reports institutional research funding and personal fees from BMS and institutional research funding from Novartis outside the submitted work. Jean‐Jacques Grob reports personal fees and nonfinancial support from BMS, Roche, MSD, Novartis, Merck, Amgen, Pierre Fabre Laboratories, Sanofi, and Pfizer and nonfinancial support from Amgen, all outside the submitted work. Julie De Quatrebarbes reports nonfinancial support from BMS, MSD, and Janssen outside the submitted work. Thierry Lesimple reports research funding and personal fees from Roche and personal fees from BMS, MSD, Novartis, Pierre Fabre Laboratories, and Incyte, all outside the submitted work. François Aubin reports personal fees and nonfinancial support from Novartis, MSD, and Roche outside the submitted work. Eve Maubec reports grants, personal fees, and nonfinancial support from MSD, personal fees from Sanofi and Novartis, personal fees and nonfinancial support from BMS, and nonfinancial support from Pierre Fabre Laboratories, all outside the submitted work. Stefan Michiels reports personal fees from IDDI Belgium, Janssen Cilag France, Hexal, Johnson & Johnson, Ipsen, Genticel, Mabxience, Steba, IQVIA, Roche, Sensorion, Biophytis, and Servier, all outside the submitted work. Céleste Lebbe reports institutional research funding, personal fees, and nonfinancial support from BMS, institutional funding and personal fees from Roche, personal fees and nonfinancial support from MSD, and personal fees from Aventis, Novartis, Amgen, Pierre Fabre Laboratories, Pfizer, and Incyte, all outside the submitted work. Isabelle Borget reports research funding from the BMS Foundation during the course of the study and personal fees from Roche, Janssen, CSC Behring, Novartis, and Takeda outside the submitted work. The remaining authors made no disclosures., Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Hôpital de la Timone [CHU - APHM] (TIMONE)-Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU)

Source: Cancer
Cancer, 2020, 126 (3), pp.611-618. ⟨10.1002/cncr.32554⟩
Cancer, Wiley, 2020, 126 (3), pp.611-618. ⟨10.1002/cncr.32554⟩

Subject Terms: Clinical practice, Immunotherapy, Metastatic melanoma, Quality of life, Real-life, Targeted therapy, MESH: Adolescent, Adult, Aged, 80 and over, Cohort Studies, Disease Progression, Female, France / epidemiology, Humans, MESH: Immunotherapy, Male, Melanoma / epidemiology, Melanoma / immunology, Melanoma / pathology, Melanoma / therapy, MESH: Middle Aged, Molecular Targeted Therapy, Neoplasm Metastasis, Neoplasms, Second Primary / epidemiology, Young Adult, MESH: Neoplasms, Second Primary / immunology, Neoplasms, Second Primary / pathology, Prospective Studies, Quality of Life, Survival Rate, [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology, Cancer Research, Oncology, Disease, Advanced disease, Medicine, business.industry, business, In real life, Cohort, Survival rate, Internal medicine, medicine.medical_specialty, Second line

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e7cc27d9b011eb68b46c2a487331eda
https://hal.archives-ouvertes.fr/hal-03227901

12
Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports

Authors: Haithem Chtioui, Marco Zezza, Carine Mekoguem, Faiza Lamine, Christophe Kosinski, Nelly Pitteloud, Laura Marino

Source: BMC Endocrine Disorders
BMC Endocrine Disorders, Vol 19, Iss 1, Pp 1-5 (2019)
BMC endocrine disorders, vol. 19, no. 1, pp. 144

Subject Terms: General Medicine, Endocrinology, Diabetes and Metabolism, Nivolumab, Type 1 diabetes, medicine.disease, medicine, Type 2 diabetes, Diabetic ketoacidosis, Ipilimumab, medicine.drug, business.industry, business, Combination therapy, Internal medicine, medicine.medical_specialty, Type 2 Diabetes Mellitus, Diabetes mellitus, Oncology, Case Report, Immune checkpoint inhibitor, Autoimmune adverse events, Endocrinopathies, endocrine system diseases, lcsh:Diseases of the endocrine glands. Clinical endocrinology, lcsh:RC648-665, Acute Disease, Aged, 80 and over, Antineoplastic Agents, Immunological/administration & dosage, Antineoplastic Agents, Immunological/adverse effects, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Diabetes Mellitus, Type 1/chemically induced, Diabetes Mellitus, Type 1/diagnosis, Diabetes Mellitus, Type 1/pathology, Female, Humans, Ipilimumab/administration & dosage, Ipilimumab/adverse effects, Male, Melanoma/drug therapy, Melanoma/pathology, Middle Aged, Nivolumab/administration & dosage, Nivolumab/adverse effects, Skin Neoplasms/drug therapy, Skin Neoplasms/pathology

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a722f98fa2436ff73199210f96e9153
https://doi.org/10.1186/s12902-019-0467-z

13
Carbidopa Alters Tryptophan Metabolism in Breast Cancer and Melanoma Cells Leading to the Formation of Indole-3-Acetonitrile, a Pro-Proliferative Metabolite

Authors: Filipa Amaro, Isabel Silva, Henrique Reguengo, Paula Fresco, Diana Duarte, José Carlos Oliveira, Jorge Gonçalves, Dany Silva, Nuno Vale

Contributors: Instituto de Investigação e Inovação em Saúde

Source: Biomolecules
Volume 9
Issue 9
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Agência para a Sociedade do Conhecimento (UMIC)-FCT-Sociedade da Informação
instacron:RCAAP
Biomolecules, Vol 9, Iss 9, p 409 (2019)

Subject Terms: indole-3-acetonitrile, tryptophan, carbidopa, MCF-7 cell line, A375 cell line, nervous system diseases, lcsh:Microbiology, lcsh:QR1-502, Molecular Biology, Biochemistry, Metabolite, chemistry.chemical_compound, chemistry, Enzyme, chemistry.chemical_classification, Breast cancer, medicine.disease, medicine, Carbidopa, medicine.drug, Kynureninase, Cancer research, Tryptophan, Aromatic L-amino acid decarboxylase, Melanoma, Breast Neoplasms / metabolism, Breast Neoplasms / pathology, Carbidopa / pharmacology, Cell Line, Tumor, Cell Proliferation / drug effects, Cell Survival / drug effects, Chromatography, High Pressure Liquid, Female, Humans, Indoles / analysis, Indoles / metabolism, Melanoma / metabolism, Melanoma / pathology, Skin Neoplasms / metabolism, Skin Neoplasms / pathology, Spectrometry, Mass, Electrospray Ionization, Tryptophan / metabolism, Article

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9138061437389dba5962460c6c79f056

HTML Full Text     PDF Full Text
14
Conjunctival melanoma copy number alterations and correlation with mutation status, tumor features, and clinical outcome

Authors: Kenawy, Nihal, Kalirai, Helen, Sacco, Joseph J., Lake, Sarah L., Heegaard, Steffen, Larsen, Ann‐Cathrine, Finger, Paul T., Milman, Tatyana, Chin, Kimberly, Mosci, Carlo, Lanza, Francesco, Moulin, Alexandre, Schmitt, Caroline A., Caujolle, Jean Pierre, Maschi, Célia, Marinkovic, Marina, Taktak, Azzam F., Heimann, Heinrich, Damato, Bertil E., Coupland, Sarah E.

Source: Pigment cell & melanoma research, vol. 32, no. 4, pp. 564-575
Pigment Cell and Melanoma Research, 32(4), 564-575
Pigment Cell & Melanoma Research

Subject Terms: Adult, Aged, Aged, 80 and over, Conjunctival Neoplasms/genetics, Conjunctival Neoplasms/pathology, DNA Copy Number Variations/genetics, DNA Mutational Analysis, Female, Humans, Kaplan-Meier Estimate, Karyotype, Male, Melanoma/genetics, Melanoma/pathology, Middle Aged, Mutation/genetics, Neoplasm Metastasis, Risk Factors, Treatment Outcome, BRAF/NRAS mutation, allele-specific copy number, conjunctival melanoma, copy number alteration, metastasis, Original Article, Original Articles, allele‐specific copy number

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::c968e78d76353a42efd8fc0f0c6052d9
https://serval.unil.ch/notice/serval:BIB_4BAB8405ADEF

15
Melanin and Neuromelanin Fluorescence Studies Focusing on Parkinson’s Disease and Its Inherent Risk for Melanoma

Authors: Ulrike Fleck, Thomas Müller, Dieter Leupold, Lukasz Szyc, Sabrina Strobel, Goran Stankovic, Hans-Ullrich Völker, Camelia-Maria Monoranu, Peter Riederer, Matthias Scholz

Source: Cells, Vol 8, Iss 6, p 592 (2019)
Leupold, D, Szyc, L, Stankovic, G, Strobel, S, Völker, H-U, Fleck, U, Müller, T, Scholz, M, Riederer, P & Monoranu, C-M 2019, ' Melanin and Neuromelanin Fluorescence Studies Focusing on Parkinson's Disease and Its Inherent Risk for Melanoma ', Cells, vol. 8, no. 6, 592 . https://doi.org/10.3390/cells8060592
Cells
Volume 8
Issue 6

Subject Terms: Parkinson’s disease, melanin, neuromelanin, dermatofluoroscopy, lcsh:Biology (General), lcsh:QH301-705.5, Adult, Aged, Aged, 80 and over, Animals, Brain/pathology, Case-Control Studies, Female, Fluorescence, Humans, Male, Melanins/metabolism, Melanoma/pathology, Middle Aged, Parkinson Disease/metabolism, Postmortem Changes, Risk Factors, Skin/pathology, Skin Pigmentation, Substantia Nigra/pathology, Article, General Medicine, Neuromelanin, Melanin, Parkinson's disease, medicine.disease, medicine, Inherent risk, Pathology, medicine.medical_specialty, Malignant transformation, Melanoma, business.industry, business, Disease, nervous system diseases

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59dcfaa0223b90177e32efdccb15df51
https://www.mdpi.com/2073-4409/8/6/592

17
Hyaluronan and its role in melanomagenesis : from melanocytes to metastatic melanoma

Authors: Takabe, Piia

Contributors: Terveystieteiden tiedekunta, Faculty of Health Sciences

Subject Terms: Hyaluronic Acid, Hyaluronan Synthases, Melanoma - pathology, Melanocytes, Fibroblasts, Stromal Cells, Cytokines, Chemokines, Cell Proliferation, Cell Division, Cell Movement, biolääketiede, biomedicine, hyaluronaani, melanooma, ihosyöpä, syöpäsolut, fibroblastit, entsyymit, sytokiinit, kemokiinit, solunjakautuminen, soluviestintä

File Description: Julkaisusta vain yhteenveto-osa

Access URL: https://explore.openaire.eu/search/publication?articleId=od______3891::9650588919977cb6e22e41f7a28c4756
http://urn.fi/URN:ISBN:978-952-61-2842-9

18
Loss of E-cadherin as Part of a Migratory Phenotype in Melanoma Is Associated With Ulceration

Authors: Lars Bastholt, Torben Steiniche, Ib J. Christensen, Tine Engberg Damsgaard, Henrik Schmidt, Holger Jon Møller, Peter Nørgaard, Allan V Danielsen, Marie Louise Bønnelykke-Behrndtz

Source: Bønnelykke-Behrndtz, M L, Steiniche, T, Nørgaard, P, Danielsen, A V, Damsgaard, T E, Christensen, I J, Bastholt, L, Møller, H J & Schmidt, H 2017, ' Loss of E-cadherin as Part of a Migratory Phenotype in Melanoma Is Associated With Ulceration ', American Journal of Dermatopathology, vol. 39, no. 9, pp. 672-678 . https://doi.org/10.1097/DAD.0000000000000750
Bønnelykke-Behrndtz, M L, Steiniche, T, Nørgaard, P, Danielsen, A V, Damsgaard, T E, Christensen, I J, Bastholt, L, Møller, H J & Schmidt, H 2017, ' Loss of E-cadherin as Part of a Migratory Phenotype in Melanoma Is Associated With Ulceration ', American Journal of Dermatopathology, vol. 39, no. 9, pp. 672–678 . https://doi.org/10.1097/DAD.0000000000000750

Subject Terms: Dermatology, General Medicine, Pathology and Forensic Medicine, Metastasis, medicine.disease, medicine, Wound healing, Inflammation, medicine.symptom, Neutrophil elastase, biology.protein, biology, Cadherin, Cell, medicine.anatomical_structure, business.industry, business, Cell morphology, Pathology, medicine.medical_specialty, Melanoma, Journal Article, E-cadherin, EMT, melanoma, ulceration, Melanoma/pathology, Humans, Skin Neoplasms/pathology, Phenotype, Cadherins/metabolism, Ulcer/pathology, Neutrophils/pathology, Inflammation/pathology, Antigens, CD, Cell Movement

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f5df6314b00fd822f28c92ffaa9eb59
https://doi.org/10.1097/dad.0000000000000750

19
Rapid and Continued T-Cell Differentiation into Long-term Effector and Memory Stem Cells in Vaccinated Melanoma Patients

Authors: Daniel E. Speiser, Laurène Cagnon, Alexandre Huber, Petra Baumgaertner, Hélène Maby-El Hajjami, Nathalie Rufer, Emanuela M. Iancu, Samia Abed Maillard, Philippe O. Gannon

Source: Clinical cancer research, vol. 23, no. 13, pp. 3285-3296

Subject Terms: Cancer Research, Oncology, Melanoma, medicine.disease, medicine, Effector, Ex vivo, T-cell receptor, Biology, Adoptive cell transfer, CD8, Immunology, Cytotoxic T cell, Stem cell, Adoptive Transfer, Antigens, Neoplasm/immunology, Antigens, Neoplasm/therapeutic use, CD8-Positive T-Lymphocytes/drug effects, CD8-Positive T-Lymphocytes/immunology, Cancer Vaccines/immunology, Cancer Vaccines/therapeutic use, Cell Differentiation/drug effects, Cell Differentiation/immunology, Freund's Adjuvant/immunology, Freund's Adjuvant/therapeutic use, HLA-A2 Antigen/immunology, Humans, Immunologic Memory/drug effects, Lipids/immunology, Lipids/therapeutic use, Lymphocyte Activation/drug effects, Lymphocyte Activation/immunology, MART-1 Antigen/immunology, MART-1 Antigen/therapeutic use, Melanoma/immunology, Melanoma/pathology, Melanoma/therapy, Stem Cells/drug effects, Stem Cells/immunology, T-Lymphocytes/immunology

File Description: application/pdf

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1dfa9ef2194b254de37b593826de748e
https://doi.org/10.1158/1078-0432.ccr-16-1708

Search Tools: Get RSS Feed — Email this Search